CRISPR Therapeutics: 2025 TIME100 Most Influential CompaniesCRISPR Therapeutics is a biotech company that borrows its name from the groundbreaking gene editing technology CRISPR. As of last year ...

The CRISPR patents are back in play. Yesterday, the US Court of Appeals for the Federal Circuit said scientists Jennifer Doudna and Emmanuelle Charpentier will get another chance to show they ...

The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.

By analogy, anyone leveraging CRISPR in biopharma R&D or embarking on CRISPR therapeutic development needs to adopt a purpose-built, thoroughly tested data management system that can weather ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation Program, which will allow innovators to have an easier path to market.

Researchers in Lithuania present the molecular structure of a new, more-versatile CRISPR system for gene editing.

A new gene editing technique derived from bacterial “jumping genes” can add, remove, recombine and invert DNA sequences, potentially overcoming some of the limitations of CRISPR. | A new gene ...

Unlike CRISPR 1.0, which hacks through DNA, CRISPR 2.0 is capable of surgical incisions, making it suitable for a broader range of gene therapy applications.

Profluent’s OpenCRISPR initiative aims to provide customizable gene editing proteins that are designed by AI from the ground up—molecules that take their inspiration from nature but have never ...

The gene-editing technique CRISPR disabled HIV that lay dormant in immune cells in a lab experiment, raising hopes for an eventual cure ...

With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot happening in the genome editing field.